MedPath

DOXYCYCLINE

Doxycycline for Injection, USP To reduce the development of drug–resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Approved
Approval ID

fa3fbb09-b830-60c5-e053-6394a90a4165

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 26, 2023

Manufacturers
FDA

FOSUN PHARMA USA INC

DUNS: 080920998

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

DOXYCYCLINE

PRODUCT DETAILS

NDC Product Code72266-237
Application NumberANDA215583
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateApril 26, 2023
Generic NameDOXYCYCLINE

INGREDIENTS (3)

ASCORBIC ACIDInactive
Quantity: 480 mg in 10 mL
Code: PQ6CK8PD0R
Classification: IACT
MANNITOLInactive
Quantity: 300 mg in 10 mL
Code: 3OWL53L36A
Classification: IACT
DOXYCYCLINE HYCLATEActive
Quantity: 100 mg in 10 mL
Code: 19XTS3T51U
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DOXYCYCLINE - FDA Drug Approval Details